Germ-line mutations in genes encoding components of the RAS/mitogen-activated protein kinase (MAPK) pathway cause developmental disorders called RASopathies. Hypertrophic cardiomyopathy (HCM) is the most common myocardial pathology and a leading cause of death in RASopathy patients. KRAS mutations are found in Noonan and cardio-faciocutaneous syndromes. KRAS mutations, unlike mutations of RAF1 and HRAS, are rarely associated with HCM. This has been attributed to the fact that germ-line KRAS mutations cause only a moderate up-regulation of the MAPK pathway. Highly bioactive KRAS mutations have been hypothesized to cause severe cardiomyopathy incompatible with life. The aim of this study was to define the impact of KRAS G12D expression in the heart.
Introduction
Germ-line mutations in KRAS, HRAS, RAF1, BRAF, and PTPN11 increase the activity of the RAS/mitogen-activated protein kinase (MAPK) pathway and lead to developmental syndromes called RASopathies. 1 RASopathies, including Noonan, Costello, and cardiofacio-cutaneous syndromes, are characterized by facial dysmorphism, reduced growth, cognitive deficits, skeletal defects, and different types of heart disorders. 2 The most common heart disorder is hypertrophic cardiomyopathy (HCM), which is associated with poor prognosis in RASopathy patients. 3, 4 Although the RASopathy genes encode proteins in the same signalling pathway, some mutations are more often associated with HCM than others. For example, RAF1 mutations cause HCM in patients with Noonan syndrome, and several Raf mutations cause HCM in mice. 5 -10 Furthermore, mutations in HRAS cause Costello syndrome and lead to HCM in the majority of patients, and mice with germ-line or cardiomyocyte-specific Hras mutations also develop HCM. 11 -14 KRAS mutations, however, found in patients with Noonan and cardiofacio-cutaneous syndromes, are rarely associated with HCM. 15 -17 A potential explanation for why HRAS mutations are associated with HCM to a higher degree than KRAS mutations is that KRAS mutations in RASopathies cause a relatively weak increase in MAPK signalling. 15 Consistent with this notion, KRAS mutations that cause RASopathies are rarely observed in cancer, whereas RASopathy HRAS mutations are often observed in cancer. 11, 18 Furthermore, cancer-causing KRAS mutations, such as KRAS G12D , are believed to be too powerful if they occurred in the germ-line and have been hypothesized to cause severe cardiomyopathy or even heart malignancy. 18 Indeed, germ-line expression of the Kras G12D mutation in mice results in cardiomegaly and embryonic lethality. 19 It is not known, however, whether cardiomegaly is the result of KRAS G12D expression in cardiomyocytes or in non-cardiac cells. Thus far, the impact of cardiomyocyte-specific KRAS G12D activation has never been evaluated. To address this issue, we generated mice with cardiomyocyte-specific expression of KRAS G12D and evaluated MAPK signalling and heart pathology. 
Echocardiography
Hair removal gel was applied to the chest of mice 1 day before echocardiography (ECG). ECG examination was performed using a VEVO 770 system with a linear RMV704 transducer (Visualsonics, Inc., Toronto, Canada) on mice anaesthetized with isoflurane inhalation ( 1.0%) and placed on a heating pad with paws connected to ECG electrodes. A rail system was used to collect ECG-gated Kilohertz Visualization in one long-axis and three short-axis parasternal projections (1, 3, and 5 mm below the mitral valves). Left ventricular ejection fraction, stroke volume, and cardiac output were calculated with biplane Simpson's formula using the three parasternal short-axis views and the parasternal long-axis view. The 3 mm short-axis projection was used for M-mode analysis. To determine cardiac reserve, we injected dobutamine (Dobutrex, 2 mg/g body weight; Eli Lilly Sweden AB, Sweden) intraperitoneally 5-8 min before repeated ECG examination. ECG data were evaluated using the VevoStrain software by an investigator blinded to mouse genotypes. All measurements were based on the average of three cardiac cycles.
Western blotting
Heart tissue from the left ventricle was homogenized in lysis buffer con- 
Histology and immunohistochemistry
Hearts were fixed in 4% paraformaldehyde, embedded in paraffin, sectioned horizontally 5 mm from the apex, and stained with Masson's trichrome. For TUNEL and CD31 staining, ventricular wall tissue was frozen in OCT compound (Sakura Finetek, Sweden). Cryosections were stained using ApopTag of heart size, cardiomyocyte cross-sectional area, fibrosis and capillary density were done with the BioPix iQ 2.1.8 software (Biopix AB, Sweden).
Statistical analysis
The values are mean + SEM. Differences between groups were analysed with Student's t-test (unpaired, two-tailed) and considered significant when P , 0.05.
Results

Cardiomyocyte-specific KRAS
G12D
expression does not affect heart size and contractility
The Kras2 LSL/+ aMHC-Cre +/0 (cKRAS G12D ) mice were born at Mendelian ratios and developed no visible signs of disease. ECG parameters were similar in 12-month-old cKRAS G12D and littermate Kras2 +/+ aMHC-Cre +/0 (control) mice. The response of hearts to dobutamineinduced stress was also similar in the two groups of mice, suggesting that the cardiac reserve was unaffected in cKRAS G12D mice ( Table 1) .
The mice were killed at 3 or 18 months of age for heart analyses. Relative heart weight and body weight were similar in cKRAS G12D and control mice ( Figure 1A and B, and see Supplementary material online, Figure  S1 ). Moreover, the size of the left ventricular lumen and the thickness of the left and right ventricular walls were not different, as assessed by image analyses of haematoxylin and eosin-stained heart sections ( Figure 1C-F) .
Expression of KRAS G12D is heart specific and starts late in embryonic development
To confirm the tissue specificity of KRAS G12D expression, DNA was extracted from heart, lung, and liver tissue of cKRAS G12D and control mice. As expected, the unrecombined Kras2 LSL allele was found in all tissues of cKRAS G12D mice, but in none of control mouse tissues. The recombined Kras2 G12D allele in adult cKRAS G12D mice was readily detected in DNA from heart tissue, but was undetectable in the lung and liver (Figure 2A) . Analyses of DNA from hearts of developing embryos revealed that the recombined Kras2 G12D allele was detected at embryonic day 20, but not at embryonic days 12 -18 ( Figure 2B) . Thus, KRAS G12D expression in cKRAS G12D mice is heart specific and begins at embryonic day 19 or 20.
To confirm bioactivity of the inducible Kras2 LSL allele in this strain of mice, we administered a Cre-adenovirus by inhalation to lungs of Kras2 LSL mice as described earlier. 20, 23 As expected, 8 weeks after
Cre-adenovirus administration, Kras2 LSL mice exhibited advanced lung tumour lesions, demonstrating that the allele produces bioactive KRAS G12D (see Supplementary material online, Figure S2 ). 
Hyperactivation of MAPK signalling pathways in the myocardium of cKRAS G12D mice
To test whether signalling downstream of KRAS was affected in hearts of cKRAS G12D mice, we performed western blots of lysates of left ventricular tissue. The levels of phospho-ERK1/2 and phospho-AKT were higher in cKRAS G12D hearts than in control hearts at 18 months of age ( Figure 2C and D), indicating a significant hyperactivity of two important pathways downstream of KRAS. Similar results were observed in hearts of 3-month-old mice ( Figure 2C and D) , suggesting that cKRAS G12D mice exhibit life-long hyperactivation of MAPK signalling in the myocardium.
Myocardial KRAS
G12D expression does not induce heart fibrosis and cardiomyocyte hypertrophy, and does not affect capillary density and protein degradation pathways Although heart function in cKRAS G12D mice was unaffected, we argued that the increased MAPK signalling might induce subclinical levels of interstitial fibrosis, cardiomyocyte hypertrophy, or apoptosiswell-known signs of myocardial pathology in humans and mice. However, this was not the case. Analyses of Masson's trichrome-stained left ventricle sections revealed similar low levels of fibrosis in cKRAS G12D and control mice ( Figure 3A) . Cardiomyocyte diameter was also unaffected in cKRAS G12D mice, ruling out cell hypertrophy, and levels of apoptosis, evaluated with TUNEL staining, were similar in the two groups of mice ( Figure 3B and C) . Based on previous studies, 24 we hypothesized that the increased phospho-AKT levels in hearts of cKRAS G12D mice might reduce myocardial capillary density. However, capillary density was similar in cKRAS G12D and control hearts at 18 months of age, as assessed by quantification of CD31 immunostaining ( Figure 3D) .
A potential explanation for the absence of hypertrophy in cKRAS G12D hearts is that activation of protein degradation pathways, such as ubiquitination or autophagy, counteracts the hypertrophic signalling. However, mRNA levels of the two main cardiomyocyte ubiquitin ligases Atrogin1 and MuRF1 and protein levels of the wellestablished autophagy markers Beclin-1, Atg5, Atg7, and LC3A were similar in cKRAS G12D and control hearts ( Figure 4A and B) . 
Discussion
In this study, we generated mice with cardiomyocyte-specific expression of KRAS G12D . Surprisingly, despite significant hyperactivation of the MAPK and AKT pathways in the myocardium, these mice did not develop heart disease.
In an earlier study, Tuveson et al. 19 showed that widespread expression of endogenous KRAS G12D (using the same Kras2 LSL allele as in the current study) leads to embryonic cardiomegaly and death. Based on this finding, it has been suggested that myocardial KRAS G12D expression is detrimental for heart function. The absence of heart disease in cKRAS G12D mice in the current study questions this conclusion.
However, there are two main differences between the mice of the two studies. Firstly, KRAS G12D expression was turned on early during embryonic development in the study by Tuveson et al. and late in the current study, suggesting that KRAS G12D expression in cardiomyocytes might be harmful for early heart development, but is well tolerated during late embryonic development and throughout life. Secondly, KRAS G12D was expressed in all tissues of the embryos in Tuveson's study and only in cardiomyocytes in the current study. Consequently, we cannot rule out the possibility that the cardiomegaly in embryos with widespread KRAS G12D expression is caused by KRAS G12D expression in cell types other than cardiomyocytes, such as heart fibroblasts or endothelial cells. The basal levels of phospho-ERK1/2 were increased in the myocardium of cKRAS G12D mice. Previously published RASopathy mouse models have not exhibited increased myocardial phospho-ERK1/2 levels under basal conditions. There is uncertainty in the literature as to whether increased MAPK activation causes HCM in RASopathies or if it is mediated by other mutation-specific mechanisms. 25 Our data clearly demonstrate that life-long hyperactivation of the ERK-MAPK pathway in cardiomyocytes does not cause HCM or other heart pathologies in mice. A potential implication of these results is that ERK -MAPK-independent pathways cause HCM in RASopathy patients, which has been suggested earlier. 26 An alternative explanation is that highly bioactive mutations, such as KRAS G12D , stimulate myocardial defence mechanisms, making them less harmful than moderately activating mutations. Two of the most important defence mechanisms that suppress pathological cardiomyocyte hypertrophy are ubiquitination and autophagy, leading to protein degradation. Markers of ubiquitination and autophagy were unaffected in cKRAS G12D hearts, suggesting that the expression of KRAS G12D does not activate known hypertrophy defence mechanisms in the heart. The cKRAS G12D mice also exhibited increased levels of myocardial phospho-AKT. AKT signalling in myocardial biology is complex. On one hand, increased AKT signalling promotes survival of cardiomyocytes and is thereby cardioprotective in mouse models of pressureoverload-induced heart failure and myocardial infarction. 27, 28 On the other hand, overexpressing AKT in cardiomyocytes results in hypertrophy and heart failure in mice. 24, 29 Our data demonstrate that life-long activation of AKT signalling by expression of physiological levels of KRAS G12D is harmless.
Expression of KRAS G12D from the endogenous promoter in mouse embryonic fibroblasts leads to reduced levels of phospho-ERK and -AKT compared with wild-type MEFs. 19 Here, we found significantly increased levels of phospho-ERK and -AKT in KRAS G12D -expressing cardiomyocytes, demonstrating that the impact of endogenous KRAS G12D on downstream signalling is cell type-specific.
There were no signs of heart malignancy in the cKRAS G12D mice, as assessed by macroscopic examination, histology, and ECG. KRAS mutations have been found in patients with cardiac rhabdomyosarcoma, a rare form of heart malignancy. 30 The likeliest explanation for the absence of malignancy in cKRAS G12D mice is that whereas endogenous KRAS G12D is sufficient to initiate tumours in many different organs in the mouse, additional genetic events are required for heart tumour formation. 19, 20, 31 We conclude that mouse hearts are resistant to cardiomyocytespecific expression of KRAS G12D despite hyperactivation of downstream ERK and AKT signalling. A clinical implication of this surprising result is that treatment of HCM in RASopathies should not only focus on targeting MAPK signalling, but also on identifying other mutationspecific downstream effects.
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